Brian Armstrong’s NewLimit Raises $435M for Human Trials
NewLimit raised $435M in Series C funding led by Founders Fund to advance its first age-reprogramming drug into human trials.
Showing 1–1 of 1
NewLimit raised $435M in Series C funding led by Founders Fund to advance its first age-reprogramming drug into human trials.